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MECHANISMS OF PROSTATE CANCER RECURRENCE 
Atsushi MIZOKAMI and Mikio NAMIKI 
From the Department oJ Urolog)らKa仰とawaUniversity 
Androgen-deprivation therapy is often the first choice of several therapeutic procedures for 
advanced prostate.cancer. However， despite an initial response to androgen-deprivation therapy， the 
cancer eventually progresses from an androgen-dependent to an androgen-independent phenotype. 
Molecular mechanism of development to androgen-independence and recurrence during androgen-
deprivation therapy remain unclear. The observation that heterogeneity of AR expression in prostate 
cancer correlates with malignancy s略gestst凶 androgenrespon町 enessplays an impor回 ltkey role in 
the progression of prostate cancer. Therefore， itis very important to consider the role of AR and 
mechanisms of relapse when we treat androgen岨independentprostate cancer. 
Key words: Recurrence， Prostate cancer， Review 
INTRODUCTION 
前立線癌の80-90%はアンドロゲン依存性である.













drogen receptor (AR)である.ARはsteroidhormone 
receptor superfamilyの中でも glucocorticoidrecep-



















1) 2) また， purine-rich regionの近傍には CpGis-
landも存在し， methylationの関与によって発現が
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Fig. 1. Structure of AR gene. AR promoter 
inc1ude a purine-rich region that is im-
portant for AR transcriptional regula-
tion， and 5'-untranslated region of AR 
mRNA inc1udes cis回actingelement im-
portant for translation. 
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mRNAの5'非翻訳領域にも翻訳に関与する重要な領










は， Tumor necrosis factor-a (TNF-α)に前立腺癌細
胞 LNCaPが長期間暴露されると，低濃度のアンド
ロゲンでも増殖を促進させることを見いだした (Fig.
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Fig. 2. Androgen-hypersensitivity of LNCaP 
cells by TNF・αLong-termexposure 
of TNF-αcauses androgen-hypersensi-
tivity， and low concentration of DHT 
stimulates LNCaP cel growth. 
Fig. 3. Interaction between AR and coactiva-
tors. CoA: coactivator， CoR: corep-
ressor， HAT: histone acetyl trans-




















第3に ARの mutationによる anti-androgen
withdrawal phenomenon. 1990年に Veldscholteら
が初めて LNCaP前立腺癌細胞で ARの ligand
binding domainに mutationがあり，そのために
anti-androgenが agonistとして作用するという報告




















Fig. 4. Mechanisms of recurrence of prostate 
cancer. 
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